Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global DNA synthesis market was valued at USD 1.25 billion in 2024 and is projected to reach USD 3.29 billion by 2031, exhibiting a CAGR of 15.2% during the forecast period. This growth is primarily driven by the increasing adoption of synthetic biology applications across pharmaceuticals, diagnostics, and industrial biotechnology sectors. The market is characterized by rapid technological advancements in gene synthesis platforms, declining costs of oligonucleotide synthesis, and expanding applications in personalized medicine and CRISPR-based therapeutics.
DNA synthesis refers to the artificial creation of deoxyribonucleic acid (DNA) molecules through chemical or enzymatic methods. This process enables researchers and biotechnology companies to obtain custom DNA fragments without relying on natural templates. The core technologies include phosphoramidite chemistry for oligonucleotide synthesis and enzymatic assembly for longer constructs. Key growth drivers include the rising demand for synthetic genes in vaccine development, particularly mRNA vaccines which require synthetic DNA templates, and the expansion of CRISPR gene editing applications which require custom guide RNAs and repair templates.
Market growth is further accelerated by significant investments in synthetic biology startups. In 2023 alone, synthetic biology companies raised over USD 7.8 billion in venture capital funding, with DNA synthesis providers capturing a significant portion of this investment. The market is moderately concentrated, with the top five players holding approximately 53% market share. Asia-Pacific represents the largest regional market with 36% share, followed by North America (35%) and Europe (26%). Within product segments, oligonucleotide synthesis dominates with 53% market share, while gene synthesis is growing at a faster rate due to increasing demand for synthetic genes in therapeutic development.
Recent industry developments include the launch of next-generation DNA synthesizers with improved throughput and error correction capabilities. In January 2024, Twist Bioscience introduced a new platform capable of producing 10,000 oligonucleotides per run with error rates below 1 in 10,000 bases. Similarly, key players such as GenScript, IDT (Danaher), and Thermo Fisher Scientific have expanded their production capacities through strategic acquisitions and facility expansions, particularly in Asia-Pacific markets where manufacturing costs are significantly lower.
The market faces several challenges including intellectual property disputes over key synthesis technologies and increasing regulatory scrutiny of synthetic genetic materials. However, the overall trajectory remains positive as pharmaceutical and biotechnology companies continue increasing their R&D investments in synthetic biology applications. Market analysts project that the DNA synthesis market will continue its strong growth through 2030, particularly as emerging applications in cell and gene therapy create new demand for custom DNA constructs at industrial scales.
Rising Demand for Synthetic Biology Applications
The increasing adoption of synthetic biology across pharmaceuticals, agriculture, and industrial biotechnology is driving demand for custom DNA synthesis. Researchers require specific genetic sequences to develop novel therapies, engineered crops, and bio-based materials, creating sustained demand for high-quality DNA synthesis services.
Expansion of Personalized Medicine
Advancements in personalized medicine, particularly in cancer treatment and gene therapy, are driving significant growth in the DNA synthesis market. The need for custom oligonucleotides for CRISPR-based therapies, CAR-T cell therapies, and other precision medicine approaches has increased dramatically, with the market seeing a 35% year-over-year increase in demand for therapeutic-grade synthesized DNA.
The global DNA synthesis market is projected to reach $8.9 billion by 2028, driven by pharmaceutical and biotechnology research demands
Increasing public and private investment in genomics research, particularly in North America and Asia-Pacific, continues to fuel market growth with major pharmaceutical companies increasing their R&D budgets by an average of 18% annually specifically for gene therapy and synthetic biology applications.
MARKET CHALLENGES
High Development and Production Costs
The significant investment required for DNA synthesis technology, including advanced equipment and specialized personnel, creates barriers to entry and limits market expansion. A single next-generation DNA synthesizer can cost upwards of $500,000, with additional costs for reagents and maintenance reaching $200,000 annually per machine. This limits accessibility for smaller research institutions and startups.
Other Challenges
Regulatory Hurdles and Standardization Issues
The lack of global standardization in DNA synthesis regulation creates challenges for international collaboration and market expansion. Different countries have varying requirements for the validation and verification of synthesized DNA, particularly for pathogenic sequences, creating compliance challenges for global market players. The World Health Organization estimates that 60% of countries lack specific regulations for synthetic DNA, creating potential safety and security concerns.
Supply Chain Constraints
The DNA synthesis market faces significant constraints from supply chain limitations, particularly in the availability of high-quality phosphoramidites and other specialty chemicals required for oligonucleotide synthesis. The 2023 global shortage of these key reagents, partly due to geopolitical tensions affecting chemical exports, caused a 40% price increase and extended delivery times, directly impacting research and development timelines across the biotechnology sector.
Emerging Markets in Asia-Pacific
The Asia-Pacific region, particularly China, India, and South Korea, presents significant growth opportunities for DNA synthesis services. With governments increasing their biotechnology research budgets by 25-30% annually and establishing new research parks specifically for synthetic biology, the region is expected to capture 38% of the global market share by 2028. Current initiatives include the establishment of 12 new national research centers focused on synthetic biology across the region, creating immediate demand for DNA synthesis services.
CRISPR and Gene Therapy Expansion
The rapid advancement of CRISPR technology and gene therapy applications is creating unprecedented demand for custom DNA sequences. With over 2,000 clinical trials currently underway globally involving gene therapies, and the FDA's increasing approval rate for gene therapy products (up 45% from 2022), the demand for high-quality, precise DNA synthesis is expected to grow exponentially. The market is responding with improved synthesis technologies that offer greater precision and reduced error rates.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Oligonucleotide Synthesis continues to be the predominant technology, serving as the foundational workhorse for a vast array of molecular biology applications from PCR primers to probes. Its widespread use is driven by its relative simplicity, cost-effectiveness for shorter sequences, and high throughput capabilities. Conversely, Gene Synthesis is experiencing dynamic growth, fueled by the expanding field of synthetic biology which requires the de novo construction of entire genes and genetic pathways for advanced research and product development, representing a key area of future expansion and technological innovation. |
| By Application |
|
Commercial applications represent the dominant force in the market, as pharmaceutical companies, biotech firms, and diagnostics manufacturers heavily rely on synthetic DNA for drug discovery, therapeutic development, and the creation of diagnostic kits. The demand is characterized by large-scale, recurring orders and stringent quality requirements. Although smaller in volume, the Academic Research segment is vital as a source of foundational innovation, driving new applications and serving as a pipeline for future commercial demand. The "Others" category includes emerging applications in data storage and novel materials science. |
| By End User |
|
Pharmaceutical & Biotechnology Companies are the primary drivers of market value, utilizing synthetic DNA for high-stakes applications like developing biologics, mRNA vaccines, and gene therapies. Their demand is characterized by a need for high fidelity, scalability, and robust intellectual property protection. While Academic & Research Institutes are essential for pioneering new uses, Contract Research Organizations (CROs) are a rapidly growing segment, acting as intermediaries that provide specialized DNA synthesis services to clients who lack in-house capabilities, thereby expanding market accessibility. |
| By Service Provider |
|
Specialized Synthesis Companies lead this segment by focusing exclusively on DNA synthesis, offering superior technical expertise, rapid turnaround times, and innovative platforms like high-throughput synthesis. They compete effectively by catering to custom and complex project requirements. In contrast, Large Life Science Corporations leverage their extensive product portfolios and global distribution networks to offer DNA synthesis as part of a broader suite of reagents and tools, providing convenience for customers seeking a single supplier. Academic Core Facilities serve the internal research community with cost-effective services. |
| By Technology |
|
Solid-Phase Synthesis is the established and dominant technology, prized for its reliability and well-optimized processes for producing high-quality oligonucleotides. Microarray-Based Synthesis is a key enabling technology for parallel synthesis, dramatically reducing costs for large-scale gene library construction and multiplexed applications, making it crucial for synthetic biology. Meanwhile, Enzymatic Synthesis is an emerging and promising technology that offers the potential for longer, more accurate sequences with fewer toxic byproducts, representing a significant area for future technological disruption and quality improvement in the field. |
A Consolidated Market Led by Synthetic Biology Pioneers
The global DNA synthesis market is characterized by a high degree of consolidation, with the top five players commanding approximately 53% of the market share. Market leadership is firmly held by a few integrated life science giants and specialized synthetic biology firms. GenScript stands as a dominant force, leveraging its extensive service portfolio in gene and oligonucleotide synthesis. It is closely followed by Thermo Fisher Scientific and Integrated DNA Technologies (IDT), both of which benefit from their vast global distribution networks and comprehensive product portfolios catering to both academic and commercial research. These leading players compete on the basis of synthesis speed, accuracy, scale, and the breadth of value-added services such as cloning and sequencing.
Beyond the market leaders, a diverse group of significant players occupies important niches. Companies like Twist Bioscience are driving innovation with high-throughput silicon-based DNA synthesis platforms, targeting large-scale synthetic biology applications. Specialized service providers such as Eurofins Genomics, Azenta Life Sciences, and ATUM (formerly DNA 2.0) have carved out strong positions by offering custom gene synthesis and optimization services for pharmaceutical and biotech clients. Regional specialists, including BBI in China and Bio Basic in North America, cater to local markets with cost-effective solutions, while others like OriGene and Bioneer focus on providing ready-to-use cloned genes and reagents. This competitive environment is further fueled by ongoing mergers, acquisitions, and technological advancements aimed at increasing synthesis efficiency and reducing costs.
List of Key DNA Synthesis Companies ProfiledGenScript
Eurofins Genomics
ATUM
BBI
Azenta Life Sciences
SBS Genetech
Bio Basic
OriGene
Bioneer
Eton Bioscience
Synbio Technologies
Eurogentec
The global DNA Synthesis market is demonstrating significant momentum, having been valued at $1250 million in 2024, with a forecast to reach $3292 million by 2031. This robust growth trajectory, representing a compound annual growth rate (CAGR) of 15.2%, is primarily driven by expanding applications within synthetic biology. DNA synthesis, as the artificial creation of DNA molecules from nucleotide monomers, provides the foundational tools for gene editing, gene cloning, and advanced biomedical research. The market's expansion is a direct reflection of the critical role synthetic DNA plays in accelerating innovation across pharmaceuticals, industrial biotechnology, and life sciences, enabling researchers to design and construct genetic sequences with unprecedented speed and precision.
Other TrendsGeographical Market Leadership and Competitive Landscape
The Asia-Pacific region has emerged as the largest market for DNA synthesis, accounting for approximately 36% of the global share, followed closely by North America (35%) and Europe (26%). The competitive landscape is concentrated, with the top five players including Genescript, Thermo Fisher Scientific, and IDT collectively holding a market share of about 53%. This concentration highlights a high level of expertise and technological advancement among leading companies, who are continuously innovating to meet the growing demand. The dominance of these players is reinforced by their extensive product portfolios and global distribution networks, while regional growth in Asia-Pacific is fueled by increasing R&D investments and a growing biotechnology sector.
Segmentation by Product and ApplicationOligonucleotide Synthesis stands as the dominant product segment, occupying 53% of the market. This is due to its widespread use in applications ranging from PCR to diagnostic assays. In contrast, Gene Synthesis is gaining traction for constructing longer, more complex sequences crucial for synthetic biology projects. On the application front, the Commercial segment is overwhelmingly dominant, holding a share of about 74%, as pharmaceutical, agricultural, and chemical companies leverage synthesized DNA for product development and optimization. Academic Research, while smaller, remains a vital segment that drives foundational discoveries and long-term innovation in the field.
Regional Analysis: DNA Synthesis MarketEurope
Europe represents a highly mature and technologically advanced market for DNA synthesis, characterized by strong collaborative research initiatives and a diverse industrial base. Countries like Germany, the United Kingdom, and France are key contributors, boasting world-class research institutions and a growing synthetic biology sector. The region benefits from significant public funding through programs like the European Union's Horizon Europe, which promotes cross-border research projects that heavily rely on custom DNA. A stringent but generally predictable regulatory environment, guided by the European Medicines Agency and other bodies, shapes market dynamics, particularly for therapeutic applications. Demand is driven by a robust pharmaceutical industry, academic research, and emerging applications in diagnostics and sustainable chemicals. While facing strong competition from North America, Europe's focus on ethical research and high-quality standards positions it as a critical and stable market.
Asia-Pacific
The Asia-Pacific region is experiencing the most rapid growth in the DNA synthesis market, fueled by increasing government investments in life sciences, a growing biotechnology industry, and cost-competitive manufacturing capabilities. China is emerging as a major force, with substantial state-backed initiatives aimed at becoming a global leader in synthetic biology. Japan and South Korea maintain strong foundational research and pharmaceutical sectors that demand high-quality synthetic DNA. India is also showing significant potential with its large pool of skilled researchers and growing contract research market. The primary growth drivers include the expansion of local biotech companies, rising academic research output, and the outsourcing of synthesis services from Western nations due to lower costs. However, the market landscape is varied, with intellectual property norms and regulatory frameworks still developing in many countries.
South America
The DNA synthesis market in South America is in a developing stage, with growth primarily concentrated in a few key countries such as Brazil and Argentina. The market is largely driven by academic and government research institutes focused on agricultural biotechnology, public health, and biodiversity studies. Limited domestic manufacturing capability means a significant portion of demand is met through imports from North American and European suppliers. Funding constraints and less developed venture capital ecosystems compared to more mature markets pose challenges for local market expansion. However, increasing awareness of synthetic biology's potential in addressing regional challenges, such as developing disease-resistant crops or novel biofuels, is gradually stimulating interest and laying the groundwork for future market growth.
Middle East & Africa
The Middle East and Africa region currently represents a smaller but emerging segment of the global DNA synthesis market. Growth is predominantly focused in a few Gulf Cooperation Council countries, notably Saudi Arabia and the United Arab Emirates, which are making strategic investments in biotechnology and life sciences as part of broader economic diversification plans. These investments are creating nascent demand for synthetic DNA in research institutions and newly established bioparks. In Africa, South Africa is the most active market, with research applications in healthcare and agriculture. Across the wider region, market development is hindered by limited infrastructure, funding challenges, and a primary focus on more immediate public health needs. Nonetheless, the potential for long-term growth exists as scientific capacity builds and international collaborations increase.
This market research report offers a holistic overview of the global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global DNA synthesis market was valued at USD 1250 million in 2024.
-> Global DNA synthesis market is projected to reach USD 3292 million by 2031.
-> Global DNA synthesis market is projected to exhibit a compound annual growth rate of 15.2% during the forecast period from 2024 to 2031.
-> Key players include Genescript, Thermo Fisher Scientific, IDT, Twist Bioscience, and BBI, among others.
-> Asia-Pacific is the largest market, holding a share of about 36%.
-> The market is segmented into Oligonucleotide Synthesis, which holds a 53% share, and Gene Synthesis.
-> Commercial applications dominate the market, accounting for approximately 74% of the market.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates